Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Authors' reply: Letter to the Editor: Regarding Karim et al. (SMMR, Vol 27, Issue 6, 2018).

Karim ME, Petkau J, Gustafson P, Platt RW.

Stat Methods Med Res. 2018 Nov 5:962280218811186. doi: 10.1177/0962280218811186. [Epub ahead of print] No abstract available.

PMID:
30392456
2.

Can We Train Machine Learning Methods to Outperform the High-dimensional Propensity Score Algorithm?

Karim ME, Pang M, Platt RW.

Epidemiology. 2018 Mar;29(2):191-198. doi: 10.1097/EDE.0000000000000787.

PMID:
29166301
3.

Estimating inverse probability weights using super learner when weight-model specification is unknown in a marginal structural Cox model context.

Karim ME, Platt RW; BeAMS study group.

Stat Med. 2017 Jun 15;36(13):2032-2047. doi: 10.1002/sim.7266. Epub 2017 Feb 20.

PMID:
28219110
4.

THE AUTHORS REPLY.

Karim ME, Gustafson P, Petkau J, Tremlett H.

Am J Epidemiol. 2016 Dec 1;184(11):857-858. Epub 2016 Nov 16. No abstract available.

PMID:
27852602
5.

Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies.

Karim ME, Petkau J, Gustafson P, Platt RW, Tremlett H; BeAMS Study Group.

Stat Methods Med Res. 2018 Jun;27(6):1709-1722. doi: 10.1177/0962280216668554. Epub 2016 Sep 21.

6.

Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.

Karim ME, Gustafson P, Petkau J, Tremlett H; Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group.

Am J Epidemiol. 2016 Aug 15;184(4):325-35. doi: 10.1093/aje/kwv445. Epub 2016 Jul 25.

7.

Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.

Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H.

Biomed Res Int. 2015;2015:451912. doi: 10.1155/2015/451912. Epub 2015 Apr 1.

8.

Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs.

Gibbs E, Karim ME, Oger J; Steering Committee of the BENEFIT study.

Clin Immunol. 2015 Mar;157(1):91-101. doi: 10.1016/j.clim.2014.12.005. Epub 2014 Dec 24.

PMID:
25543089
9.

Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H.

Am J Epidemiol. 2014 Jul 15;180(2):160-71. doi: 10.1093/aje/kwu125. Epub 2014 Jun 17.

10.

Can joint replacement reduce cardiovascular risk?

Karim ME.

BMJ. 2013 Nov 20;347:f6651. doi: 10.1136/bmj.f6651. No abstract available.

PMID:
24259322
11.

Interferon beta and long-term disability in multiple sclerosis.

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.

JAMA Neurol. 2013 May;70(5):651-2. doi: 10.1001/jamaneurol.2013.2197. No abstract available.

PMID:
23699948
12.

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.

JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.

PMID:
22797642

Supplemental Content

Loading ...
Support Center